Drugs / BCD-236
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07108309 | Jul 2024 → Dec 2025 overdue | triple-negative breast carcinoma | Biocad | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07108309 ↗ |
| Route | Intravenous | “as an intravenous infusion” NCT07108309 ↗ |